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ABSTRACT
Objective: Prior to 2005, Irish citizens had exclusively
availed of lung transplantation services in the UK.
Since 2005, lung transplantation has been available to
these patients in both the UK and Ireland. We aimed to
evaluate the outcomes of Irish patients undergoing
lung transplantation in both the UK and Ireland.
Design: We retrospectively examined the outcome of
Irish patients transplanted in the UK and Ireland. Lung
allocation score (LAS) was used as a marker of disease
severity.
Results: A total of 134 patients have undergone
transplantation. 102 patients underwent
transplantation in the UK and 32 patients in Ireland. In
total, 52% were patients with cystic ﬁbrosis, 19% had
emphysema and 15% had idiopathic pulmonary
ﬁbrosis. In Ireland, 44% of the patients suffered from
idiopathic pulmonary ﬁbrosis, 31% had emphysema
and 16% had cystic ﬁbrosis. A total of 96 double
sequential transplants and 38 single transplants have
been performed. LAS of all patients undergoing lung
transplantation was 37.8 (61.02). The mean LAS for
patients undergoing lung transplantation in Ireland was
44.7 (63.1), and 35 (60.4) for patients undergoing
lung transplantation in the UK (p<0.05). The 5-year
survival of all Irish citizens who had undergone lung
transplantation was 73%. The 5-year survival of Irish
patients transplanted in the UK was 69% and in Ireland
was 91% and 73% at 5.01 years.
Conclusions: International collaboration can be
achieved, as evidenced by the favourable outcomes
seen in Irish citizens who undergo lung transplantation
in both the UK and Ireland. Irish citizens undergoing
lung transplantation in Ireland have a higher LAS
score. Despite excellent outcomes, an intention-to-
treat analysis of the treatment utility (transplant)
indicates the limited effectiveness of lung
transplantation in Ireland and emphasises the need for
increased rates of lung transplantation.
INTRODUCTION
Lung transplantation was developed in the
1980s to provide a treatment for advanced
lung diseases, including cystic ﬁbrosis (CF),
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ARTICLE SUMMARY
Article focus
- Determine the survival outcomes following lung
transplantation for Irish patients undergoing lung
transplantation in experienced UK programmes
and a newly established transplant programme
in Ireland.
- Compare recipient lung allocation scores (a
marker of disease severity) between programmes.
Key messages
- International collaboration for complex medical
services can be achieved, as demonstrated by
the favourable outcomes seen in Irish citizens
who undergo lung transplantation in both in the
UK and Ireland.
- Irish citizens undergoing lung transplantation in
Ireland have a higher LAS (44.7 (63.1) vs 37.8
(61.02)), suggesting that local services can
accommodate patients with a greater disease
burden.
- Despite excellent outcomes, an intention-to-treat
analysis of the treatment utility (transplant)
indicates the limited effectiveness of lung trans-
plantation in Ireland and emphasises the need for
increased rates of lung transplantation.
Strengths and limitations of this study
- This study is unique in that it gives insight into an
Anglo-Irish collaboration delivering a successful
highly complex service to severely ill patients. It
shows excellent outcomes and offers a platform
on which further development may result in
increase levels of transplant activity beneﬁting
both Ireland and the UK. A limitation of the study
is the modest number of lung transplants in
Ireland.
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Open Access Researchemphysema and idiopathic pulmonary ﬁbrosis (IPF).
From the years 1990 to 2000, lung transplantation was
available in the UK for Irish patients who were selected
and referred on an ad hoc basis by individual physicians.
In 2000, the Irish Department of Health and Children
(DOHC) formally commissioned and funded a service-
level agreement with the Freeman Hospital in Newcastle,
UK, to provide lung transplantation for Irish patients. In
2005, a new clinical service providing lung trans-
plantation was initiated at the Mater Misericordiae
University Hospital (MMUH), Dublin, Ireland. In addi-
tion to being a signiﬁcant step-forward for the provision
of healthcare services in Ireland, it was also a unique
development as the majority of national lung transplant
programmes had been initiated in the years between
1985 and 1990. Therefore, the newly commissioned
programme in Ireland was required to provide a lung
transplant service to Irish patients in a manner that was
already available in long established successful lung
transplant programmes in the UK.
The aims of this study were therefore to determine the
survival outcomes following lung transplantation for
Irish patients undergoing lung transplantation in the UK
and Ireland and to benchmark these for disease severity.
MATERIALS AND METHODS
Study population
Data from the National Lung Transplant Unit Database
at MMUH were examined from 2000 to 2011. Irish citi-
zens transplanted in the MMUH, the Freeman Hospital
in Newcastle, UK, Hareﬁeld Hospital in Middlesex, UK,
and Great Ormond Street in London were included in
the study. Chart records of all patients who had under-
gone lung transplantation were examined. Demographic
variables including age, gender, race, waiting-list time
and primary diagnosis were documented. Patients
received centre-speciﬁc immunosuppression. In the
MMUH, patients received basiliximab induction therapy
followed by triple therapy, including mycophenolate
mofetil, tacrolimus and steroids.
Calculation of lung allocation score (LAS)
LAS was used as a measure of disease severity.
1 2 LAS
values for patients were calculated using the Organ
Procurement and Transplantation Network calculator.
The LAS immediately prior to lung transplantation was
used. The LAS score included the diagnosis of the
patient (eg, emphysema, CF, etc), age of the patient,
body mass index, presence or absence of diabetes
mellitus, ability to function according to the New York
Heart Association Scale, percentage of predicted forced
vital capacity, systolic pulmonary artery (PA) pressures,
mean PA pressures, pulmonary capillary wedge pressure,
ﬂow rate of supplemental oxygen required at rest, 6-min
walk test, need or lack of need for continuous mechan-
ical ventilation and levels of creatinine in the blood.
Organ Procurement and Transplantation Network
default haemodynamic values for systolic PA pressures,
mean PA pressures and pulmonary capillary wedge
pressure were entered into the LAS calculation if the
value was missing.
LAS scores for each patient were calculated on clinical
information relating to the immediate pre-lung
transplantation period.
Sixteen patients with CF did not have real-time
pre-transplant data, and therefore, the LAS score was
analysed in the 54 patients with CF.
Survival analysis
Survival time for Irish citizens who underwent lung
transplantation in the UK and at the MMUH, Dublin, was
calculated from the time of lung transplant to the time of
death or to the censoring of data on 1 March 2011.
Survival time for patients awaiting transplantation in
MMUH was calculated from time of listing for lung
transplantation to the time of death or to the censoring
of data on 1 March 2011. Survival analysis was performed
using the KaplaneMeier and log-rank tests.
An intention-to-treat analysis of all patients who were
listed for transplantation in Ireland was performed to
estimate treatment effectiveness. This was performed by
calculating the survival of all patients listed for trans-
plantation. It combined the survival times of those who
died awaiting transplantation and those who received
a transplant.
Statistical analysis
Normally distributed data were presented as means
(6SEM). Statistical comparisons of means were made
using analysis of variance. For non-normally distributed
data, two group comparisons of the means were made
using the ManneWhitney U test and Kolmogorove
Smirnov two-sample tests. A value of p<0.05 was
accepted as statistically signiﬁcant.
The log-rank test was used to examine survival differ-
ences. The statistical software SPSS (V.18) was used for
all analyses.
RESULTS
Patient characteristics
A total of 134 Irish citizens have undergone lung trans-
plantation. To date, 52% of transplanted patients
suffered from CF, 19% had emphysema and 15% had
IPF. The remaining 13% of patients had a variety of
diagnoses, including lymphangioleiomyomatosis, bron-
chiectasis, sarcoidosis, Eisenmenger’s syndrome and
primary pulmonary hypertension. A total of 96 double
sequential lung transplants and 38 single transplants
have been performed (table 1). Fifty-one per cent of lung
transplant recipients were male. There was no statistical
difference between baseline characteristics of male and
female patient groups. The mean age of patients with CF
was 26.1 (61) years, patients with emphysema was 53.7
(61.3) years and patients with idiopathic pulmonary
ﬁbrosis (IPF) was 56.3 (61.4) years.
Between 2005 and 2011, 32 patients had undergone
transplantation at the MMUH, Dublin. There were 17
male and 15 female patients. Compared to the UK,
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Survival of Irish citizens following lung transplantationa higher proportion (44%) of these patients suffered
from IPF, while 31% had emphysema, 16% had CF and
equal number of the remainder of patients had
lymphangioleiomyomatosis (3%), sarcoidosis (3%) and
bronchiectasis (3%) (refer to table 1). The mean age of
patients with CF was 28.0 (63.1) years, patients with
emphysema was 57.1 (61.4) years and patients with IPF
was 58.1 (61.4) years. All patients had a BMI<28.
Patients with IPF on the active transplant list waited 1.05
(60.23) years for transplantation, patients with CF waited
1.09 (60.13) years and patients with emphysema awaited
1.65 (60.28) years. There was no statistical difference in
waiting times in the different disease groups.
Lung allocation scores
The mean LAS of all Irish citizens undergoing lung
transplantation was 37.8 (61.02) (table 2). The mean
LAS for patients undergoing lung transplantation in
MMUH was 44.7 (63.1), which was signiﬁcantly greater
than the mean LAS (35.060.4) for Irish citizens under-
going lung transplantation in the UK (p<0.05) (table 2,
ﬁgure 1). The mean LAS of all patients with IPF was 51.0
(63.5). LAS for patients with IPF transplanted in
MMUH was signiﬁcantly greater (p<0.05) than those
transplanted in the UK centres.
Survival
The 5-year survival of all Irish citizens who underwent
lung transplantation (n¼134) was 73% (ﬁgure 2). The
5-year survival of Irish patients transplanted in the
UK centres (n¼102) was 69%. The 5-year survival of
Irish citizens undergoing lung transplantation in
MMUH, Dublin (n¼32) was 91% (with the use of log-
rank test, MMUH vs UK centres, p<0.05). One patient
died from liver cirrhosis after 5.01 years bringing the
MMUH survival to 73%. This was closer to the UK
survival curve at 5 years (ﬁgure 2).
Of those patients awaiting lung transplantation, the
median estimates of survival was 1.3 years (95% CI 0.6 to
2.0). IPF was the leading cause of death. There was
a clear survival beneﬁt with transplantation (with the use
of log-rank test, p<0.001). Three patients experienced
bronchiolitis obliterans syndrome within 5 years of
transplantation, of whom two died.
Intention-to-treat analysis
The intention-to-treat analysis showed a signiﬁcantly
reduced survival when compared to standard post-
transplant survival (p<0.001) (ﬁgure 2).
DISCUSSION
All Irish citizens who underwent lung transplantation in
both the UK and Ireland experienced a signiﬁcant
survival beneﬁt. This study indicates that a newly
commissioned lung transplant programme can deliver
quality outcomes comparable to and exceeding the
international averages. Patients undergoing lung
Table 1 Patient characteristics
Disease Total number Male/female Lung Tx Tx centres
Cystic ﬁbrosis 70 38/32 70 D 5M, 59N, 4H, 2G
Emphysema 25 11/14 11D, 14S 10M, 14N, 1H
Idiopathic pulmonary ﬁbrosis 20 13/7 3D, 17S 14M, 5N, 1H
Lymphangioleiomyomatosis 3 0/3 1D, 2S 1M, 2N
Bronchiectasis 6 4/2 5D, 1S 1M, 4N, 1H
Sarcoidosis 5 1/4 2D, 3S 1M, 4N
Eisenmenger’s syndrome 2 1/1 1D, 1S 2N
Primary pulmonary hypertension 3 1/2 3D 3N
Total 134 69/65 96D, 38S 32M, 93N, 7H, 2G
The disease subtype, total number of transplants performed, male to female distribution, double (D) or single (S) transplants (Tx) and the
number of transplants performed within the respective centre (M, Mater; N, Newcastle; H, Hareﬁeld and G, Great Ormond Street) are shown.
Table 2 Disease subtypes and LAS
Disease
All centres UK centres MMUH
LAS n LAS n LAS n
Cystic ﬁbrosis 35.260.3 54 35.460.3 49 33.160.7 5
Emphysema 32.460.4 25 32.160.7 15 32.960.4 10
Idiopathic pulmonary ﬁbrosis 51.063.5 20 40.561.57 6 55.564.5* 14
Lymphangioleiomyomatosis 35.160.8 3 35.561.7 2 34.2 1
Bronchiectasis 34.561.3 3 33.260.4 2 37.2 1
Sarcoidosis 48.6613.6 4 35.162.9 3 88.9 1
Eisenmenger’s syndrome 28.6 1 28.6 1 ee
Total 37.861.02 110 35.060.4 78 44.763.1* 32
*Signiﬁcant difference between LAS of patients transplanted in MMUH and LAS of patients transplanted in UK centres (p<0.05).
Disease subtypes and average LAS (6SEM) in all centres, UK centres and MMUH are shown. The number of patients used to calculate each
LAS is shown in each disease subtype.
LAS, lung allocation score; MMUH, Mater Misericordiae University Hospital.
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Survival of Irish citizens following lung transplantationtransplantation in Ireland have a 5-year survival of 91%
compared to 69% in the UK and 60% internationally.
3
These favourable outcomes do not appear to be the
result of selecting ‘easier’ cases. LAS, a surrogate of
disease severity, was signiﬁcantly higher in patients
undergoing lung transplantation in Dublin compared to
Irish patients undergoing lung transplantation in the
UK. This indicates that the provision of local services
may facilitate the delivery of care to higher risk cases.
4 In
Ireland, although transplantation provided a survival
advantage to those who received the treatment, its
overall effectiveness was undermined by the high
mortality on the waiting list, as demonstrated by the
intention-to-treat analysis. Prior to 2000, Irish patients
requiring lung transplantation were referred by paedi-
atric and adult respiratory physicians on an ad hoc basis
to any one of ﬁve centres in the UK. In the 1990s, there
were approximately 22e24 Irish patients awaiting trans-
plantation in the UK annually, with an average of one
patient receiving a lung transplant annually. The
response from the DOHC in Ireland was to commission
a transplant programme at the MMUH, Dublin. This
programme was planned and developed in a coherent
logical way and commenced by linking with a centre
(Freeman Hospital Newcastle) in the UK. This ‘buddy’
strategy was underpinned by a ﬁnancial contract from
the DOHC to ensure Irish patients underwent treat-
ment. The provision of local services in Dublin was then
progressed in three phases. The ﬁrst stage that
commenced in May 2002 involved the deployment of
dedicated services for the assessment and medical follow-
up of patients who had undergone lung transplantation.
The second phase involved the development of a waiting
list of Irish patients who wished to undergo lung trans-
plantation in Dublin. This took 3 years and culminated
in the ﬁrst lung transplant being successfully performed
in May 2005. The next step involved the selection of
patients who required a double lung transplant, and this
was performed in January 2006. This then prompted the
selection of patients with CF for lung transplantation
culminating in the ﬁrst double lung transplant for CF
being performed in July 2007. Based on the favourable
data set, only patients with unusually complex needs will
travel to the UK for services. However, because of the
links between the UK and Ireland, two common
misconceptions emerged. The ﬁrst of these was that Irish
patients can be on both the Irish and the UK waiting lists
at the same time. This is not possible because such an
arrangement may result in a subset of patients being
treated more favourably. The second misconception
is that the UK services guarantee a transplant and the
Irish system does not. Regrettably, the mortality of
patients awaiting lung transplantation is likely to be
comparable in both services. Indeed, the mortality
for the subset of patients with IPF approaches 50%.
Consequently, the core challenge for the emerging
Irish programme is to increase the quantity of
transplants.
An annual transplant rate of six to eight per annum in
Ireland is modest, and it is recognised that ‘small
volume’ programmes are associated with an increased
risk of mortality following transplantation. However,
a recent study also indicated that ‘small volume’
programmes can have excellent outcomes.
5 That study
highlights an additional variable of a ‘centre effect’.
Individual programmes despite the volume activity can
deliver favourable outcomes when compared to ‘large
volume’ programmes.
In Ireland, although transplantation provided
a survival advantage to those who received the treatment,
its overall effectiveness was undermined by the high
Figure 1 Lung allocation scores (LAS). MMUH, Mater
Misericordiae University Hospital. Mean bar is shown.
*p<0.05.
Figure 2 Survival curve of Irish patients. KaplaneMeier
survival curves of patients transplanted in Mater Misericordiae
University Hospital (MMUH), patients transplanted in UK
centres, combined all centres survival (UK centres and MMUH)
and Irish patients awaiting transplant in Ireland. Intention-to-
treat analysis evaluating treatment effectiveness demonstrates
a signiﬁcantly poorer survival compared to post-transplant
survival (with the use of log-rank test, p<0.0001).
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following transplantation are excellent, the intention-to-
treat analysis emphasises the critical need for greater
numbers of transplants. The required increase in quan-
tity of lung transplantation presents a complex challenge
that demands overall system changes within the Irish
health service. Ireland has been the only European
country that did not have a speciﬁc transplant organi-
sation prior to 2010. In 2010, the European Directive for
organ transplantation has stated that each jurisdiction
must have a speciﬁc transplant organisation, which is
responsible for audit, registration of donors, safety from
infectious complications and the governance of trans-
plant activity.
6 These issues are now currently being
addressed by a newly constituted National Organ
Donation and Transplantation ofﬁce within the Irish
Health Service Executive.
At the MMUH only those donors who fulﬁlled the
recommended International Society of Heart Lung
Transplantation criteria for donation were selected.
Marginal lungs were not used. Both Ireland and the UK
have among the lowest lung utilisation rates in Europe.
5
Organ care programmes in Canada and Australia have
resulted in increased quantity of lung transplants.
78In
Ontario in particular, such strategies have resulted in
a radical increase of the number of lungs used from 15%
to 55%. Cadaveric lobar transplantation, ex vivo lung
perfusion of marginal donor lungs and donation after
cardiac death can increase the quantity of organ
donors.
91 0In the event that similar processes can be
deployed in the Irish health service, it is probable that
the quantity of lung transplants per annum will be
enhanced, potentially resulting in a greater capacity to
share organs across the UK and Ireland.
In conclusion, our data indicate favourable outcomes
for Irish citizens undergoing lung transplantation in both
the UK and Ireland. Furthermore, prospective planning
with international collaboration allows the successful
delivery of complex high-end services to patients.
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